Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04856085 · ClinicalTrials.gov registry record · Phase 2
Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
A Phase 2 study of Hepatitis B， Chronic, sponsored by Vir Biotechnology.
- Active
- Registry status
- Phase 2
- Development phase
- 244
- Enrollment target
- 20
- Study locations
NCT04856085: Active Phase 2 study of Hepatitis B， Chronic, sponsored by Vir Biotechnology.
NCT04856085 is a Phase 2 study of Hepatitis B， Chronic that is active but no longer recruiting, run by Vir Biotechnology. The registered enrollment target is 244 participants, below the 566-participant average among 6 other Hepatitis B， Chronic trials with a reported enrollment target (57% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04856085, a Phase 2 study of Hepatitis B， Chronic, is active but no longer recruiting, sponsored by Vir Biotechnology.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 244 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 2 study in which participants with chronic hepatitis B virus (HBV) infection will receive VIR-2218, VIR-3434 and/or PEG-IFNα and be assessed for safety, tolerability, and efficacy
Conditions Studied
Interventions
- DRUG VIR-2218
- DRUG VIR-3434
- DRUG PEG-IFNα
Study Locations (20)
Other
- Investigative Site - Toronto
- Investigative Site - Toronto
- Investigative Site - Vancouver
- Investigative Site - Frankfurt
- Investigative Site - Hanover
- Investigative Site - Mannheim
- Investigative Site - Hong Kong
- Investigative Site - Kuala Lumpur
- Investigative Site - Chisinau
- Investigative Site - Auckland
- Investigative Site - Auckland
- Investigative Site - Hamilton
- Investigative Site - Tauranga
Florida
- Investigative Site - Miami
- Investigative Site - Orlando
California
- Investigative Site - San Francisco
Maryland
- Investigative Site - Baltimore
New Jersey
- Investigative Site - Hillsborough
Shatin
- Investigative Site - Hong Kong
Tai Po District
- Investigative Site - Hong Kong
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 244 participants |
| Start Date | 2021-07-11 |
| Est. Completion | 2026-03 |
| Phase | Phase 2 |
What the registry record for NCT04856085 still lists
NCT04856085 is an interventional study that assigns participants to a tested intervention. The registered 244 participants enrollment target is mid-sized for trials with a published cap, below the 566-participant average among 6 other Hepatitis B， Chronic trials with a reported enrollment target (57% lower).
The record links to 1 condition, with Hepatitis B， Chronic appearing as the primary indexed condition, and to 3 interventions - of which VIR-2218 is the first listed.
NCT04856085 names 20 study sites across 7 states, led by Other, Florida, California.
Frequently Asked Questions
What is clinical trial NCT04856085 about?
NCT04856085 is a clinical study titled "Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection". This is a phase 2 study in which participants with chronic hepatitis B virus (HBV) infection will receive VIR-2218, VIR-3434 and/or PEG-IFNα and be assessed for safety, tolerability, and efficacy
What is the current status of trial NCT04856085?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 244 participants. The study started on 2021-07-11. Estimated completion is 2026-03.
What conditions does trial NCT04856085 study?
This clinical trial studies the following conditions: Hepatitis B， Chronic.
What interventions are being tested in trial NCT04856085?
The interventions under investigation include: VIR-2218 (DRUG), VIR-3434 (DRUG), PEG-IFNα (DRUG).
Who is sponsoring clinical trial NCT04856085?
This trial is sponsored by Vir Biotechnology, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04856085 being conducted?
This trial has 20 study locations across California, Florida, Maryland, New Jersey, Shatin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis B， Chronic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The HOPE Study: Characterizing Patients With Hepatitis B and C
RECRUITING
-
Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B
RECRUITING · Phase 1
-
Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)
ACTIVE NOT RECRUITING · Phase 3
-
Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)
ACTIVE NOT RECRUITING · Phase 3
-
Collection of Samples for the Clinical Evaluation of the Aptima HBV (Hepatitis B Virus) Quant (Quantification) Assay
COMPLETED
-
Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02227251 · 244 participants · Phase 2
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- NCT04317534 · 244 participants · Phase 2
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
- NCT04683250 · 244 participants · Phase 1
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
- NCT04686305 · 244 participants · Phase 1
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI